Led by Professor Gert Attard and comprised of one Principal Research Fellow, two Senior Research Fellows and four Research Fellows, of which four are computational biologists, nine Clinical Fellows, one PhD student, five Research Assistants and a lab manager, the Treatment Resistance Group has its home at the UCL Cancer Institute, London.
Professor Gerhardt Attard
Prof Attard is a John Black Charitable Foundation Endowed Chair in Urological Cancer Research at University College London.
He holds an advanced Cancer Research UK Clinician Scientist award and is Team Leader of the Treatment Resistance Group at the UCL Cancer Institute.
He graduated with a degree in Medicine from the University of Malta in June 1999 and obtained a PhD in Medicine from the University of London (ICR) in 2010.
His main research interest is dissecting treatment resistance, currently with a focus on plasma DNA analysis, in order to inform on the development of novel therapeutics and biomarkers for castration resistant prostate cancer (CRPC).
He is an experienced clinical trialist in CRPC and a co-author of more than 130 peer-reviewed manuscripts, including several important papers on advanced prostate cancer.
Prof Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investigator Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010.
He received the Cancer Research UK Future Leader Award in 2017.
Prof Attard sits on a number of advisory boards and is the GU associate editor of Annals of Oncology.